Discrimination index The preference for and therefore recognition of the novel object, the novel arm in the Y maze, or the mouse over the empty cage were assessed by calculating the discrimination index (Ennaceur & Delacour, 1988): The discrimination indices of all genotype and treatment groups were compared individually with a theoretical value of 0, which would indicate no preference for the novel or familiar object, Y maze arm, or cage with mouse over empty cage using a one-sample t test
Tirzepatide is the active ingredient in Mounjaro and Zepbound
Cycle Strategies For AOD-9604 Peptide AOD9604 is typically run in short cycles rather than continuous year-round use: Cycle Length: 412 weeks, depending on body composition goals Break Periods: Taking 24 weeks off between cycles may help maintain sensitivity and responsiveness Expected Results: Clinical data shows reductions in fat mass may start appearing after 68 weeks of consistent use, but results vary based on diet, training, and metabolic health (trial overview) Stacking AOD9604 with Other Peptides or Supplements Many athletes and clinics stack AOD9604 with other compounds to enhance its fat-burning potential: CJC1295 + Ipamorelin Promotes growth hormone release, potentially amplifying fat-loss effects
After binding to the receptors, TGF- can participate in the EndMT via Smad (Small Mother against Decapentalegic) and non-Smad (MAPK, ERK, etc.) pathways
